Study Stopped
No results are avaialble as the study did not complete according to the protocol
Survey in Post-menopausal Women Followed up After Treatment With Anastrozole as Adjuvant Therapy
ARIES
A Report Upon a Cohort of Post-menopausal Women Followed up After Treatment With Anastrozole as Adjuvant Therapy for Hormone-dependant Breast Cancer. Long-term Tolerance Evaluation
1 other identifier
observational
1,840
0 countries
N/A
Brief Summary
The purpose of this survey is to describe long-term tolerance as seen under current conditions of use for anastrozole.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Nov 2005
Longer than P75 for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
November 1, 2005
CompletedFirst Submitted
Initial submission to the registry
October 9, 2007
CompletedFirst Posted
Study publicly available on registry
October 11, 2007
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2011
CompletedStudy Completion
Last participant's last visit for all outcomes
June 1, 2011
CompletedFebruary 7, 2013
February 1, 2013
5.6 years
October 9, 2007
February 6, 2013
Conditions
Keywords
Eligibility Criteria
Woman seen by their physician in the current care setting and for whom a treatment with anastrozole is decided by the physician (adjuvant treatment of breast cancer in postmenopausal women with hormone receptor positive status)
You may qualify if:
- woman treated with anastrozole as adjuvant therapy for hormone-dependant breast cancer in post-menopausal women with positive hormone-receptors
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- AstraZenecalead
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
AstraZeneca France Medical Director
AstraZeneca
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
October 9, 2007
First Posted
October 11, 2007
Study Start
November 1, 2005
Primary Completion
June 1, 2011
Study Completion
June 1, 2011
Last Updated
February 7, 2013
Record last verified: 2013-02